Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
Open Access
- 25 November 2002
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 162 (21) , 2478-2486
- https://doi.org/10.1001/archinte.162.21.2478
Abstract
BY 1997, the dramatic success of highly active antiretroviral therapy in reducing acquired immunodeficiency syndrome (AIDS)–related mortality led to clinical guidelines that recommended early initiation of treatment for human immunodeficiency virus (HIV)–infected individuals with asymptomatic disease, regardless of CD4 cell count.1,2 Since then, however, adverse effects associated with longer-term antiretroviral therapy have been identified, including cholesterol changes, fat redistribution symptoms, impaired glucose tolerance, and osteopenia.3-9 Concerns about these long-term adverse effects have contributed to a reevaluation of recommendations about when to initiate treatment.10-12Keywords
This publication has 2 references indexed in Scilit:
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000HIV Research & Clinical Practice, 2000